Johnson & Johnson Family of Companies
NEWS
Following first-quarter results, Johnson & Johnson is projecting almost $1 billion less in revenue for the year than the initial guidance it gave in January.
Pfizer, J&J and GSK indicate plans to file for regulatory approval by the end of this year for vaccines against RSV, which would see vaccines against the disease becoming available in 2023.
The FDA has sprung into action, cracking down on the illegal sales of Adderall, as well as on CBD companies making claims their products are effective treatments or cures for COVID-19.
Janssen Pharmaceutical, under parent organization Johnson & Johnson, secured an arbitrary win this week that results in royalty decisions stemming from licensing and marketing of daratumumab.
COVID-19 has killed more than six million people worldwide and almost one million in the U.S. And the pandemic isn’t over yet. Read on for that and more updates about COVID-19.
Global health officials are monitoring COVID-19 cases with an eye to identifying the emergence of new, potentially more deadly or more infectious variants. Read on for more details.
Here’s a look at the eight most profitable biopharma companies around the world. Profitability, in this case, refers to net income, as opposed to total revenue or sales.
Although it looks that we’re on the downside of the COVID-19 pandemic in the U.S., biopharma companies are still working on developing better treatments and preventions.
COVID-19 vaccines are the most-studied vaccines in history. This is partly why some data can appear so contradictory. For those and more COVID-19 stories, continue reading.
JOBS
IN THE PRESS